New drug combo aims to stop Chemo-Induced nausea in cancer patients

NCT ID NCT07617246

Recruiting now Symptom relief Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a combination of two drugs, fosrolapitant and palonosetron, plus a steroid, can prevent nausea and vomiting caused by chemotherapy and immunotherapy in people with esophageal or lung cancer. About 120 participants will receive the drug before each chemo cycle. Researchers will track how many patients have no vomiting or need for rescue medication during the first week after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fosrolapitant and Palonosetron Hydrochloride for Injection combined with dexamethasone acetate
What this could lead to: If it works, this could provide a more effective way to prevent nausea and vomiting during cancer treatment, improving patients' quality of life.
What could go wrong: This is an early phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may not work better than existing options, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGUS CANCER LUNG CANCER

Contacts and locations

Locations

SAHZhejiangU
RECRUITING

Hangzhou, Zhejiang, 313000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.